JMP Securities Reiterates Market Outperform on Karuna Therapeutics, Maintains $318 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler reiterated a Market Outperform rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a $318 price target.
June 01, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jason Butler reiterated a Market Outperform rating on Karuna Therapeutics and maintained a $318 price target.
The reiteration of the Market Outperform rating and maintenance of the $318 price target by JMP Securities analyst Jason Butler indicates a positive outlook for Karuna Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100